CEO G V Prasad said the announcement is in line with its renewed strategy to enable us achieve self-sustainability

The drug maker said the audit of its API manufacturing plant at Miryalaguda in Telangana, by the US FDA, has been completed.

Here's a look at the top stocks that may hog the limelight in today's session.

Phase II studies for DFA-02 have been successfully completed and the product will now be transitioning to Phase III registration studies.

The drug is intended to be used for the prevention of surgical site infections, following non-emergency, elective colorectal surgery.

This adds to another milestone for the Promius Pharma, committed to develop innovative treatment options in dermatology space, spray to be ...

Dr Reddy's Laboratories (DRL) today said its acute migraine treatment injection ZembraceSymTouch is now commercially available in the US ma...

The company said its US subsidiary Promius Pharma has received USFDA approval to market Sernivo spray, used in treatment of skin disorder.

The approvals have come at a time when Indian drug companies are facing the FDA’s ire for non-compliance of good manufacturing process.

Promius Pharma LLC, the company's US arm will be responsible for commercialising Zenavod in the US market, it added.

The stock gained 3.21 per cent to settle at Rs 3,103.60 on BSE. Intra-day, it rose 3.58 per cent to Rs 3,115.

The company has received an approval from the US Food and Drug Administration (USFDA) for ZembraceSymTouch injection, DRL said in a stateme...

Dr Reddy's said Hatchtech in September 2014 had announced positive results from its two pivotal phase three clinical studies.

Of them, the two NDAs are the first dermatology applications submitted to the US regulator that were fully developed leveraging in-house ca...

Drug-maker Dr Reddy’s Laboratories (DRL) is now eyeing brand acquisitions in the US rather than buying firms to strengthen its dermatology ...